论文部分内容阅读
目的:探讨卡泊芬净治疗白血病化疗患者合并肺部侵袭性真菌感染(IFI)的临床疗效及安全性分析。方法:将147例合并肺部侵袭性真菌感染的白血病化疗患者分为观察组与对照组两组。观察组采用卡泊芬净治疗,对照组采用两性霉素B治疗;对比两组疗效,真菌清除情况及不良反应的发生情况。结果:观察组真菌清除率为87.50%,对照组真菌清除率为60.00%,两组差异有统计学意义(χ~2=6.116,P<0.05);观察组疗效显著高于对照组,差异有统计学意义(Z=3.056,P<0.05);观察组不良反应的发生率(10.96%)显著低于对照组(25.68%),差异有统计学意义(χ~2=5.308,P<0.05)。结论:卡泊芬净治疗白血病化疗合并肺部侵袭性真菌感染的疗效确切,具有较强的抗真菌效果,且不良反应发生率低。
Objective: To investigate the clinical efficacy and safety of caspofungin in the treatment of patients with leukemia chemotherapy combined with pulmonary invasive fungal infection (IFI). Methods: A total of 147 patients with leukemia with pulmonary invasive fungal infection were divided into observation group and control group. The observation group was treated with caspofungin, the control group was treated with amphotericin B; the curative effect, fungal elimination and adverse reactions were compared between the two groups. Results: The fungal clearance rate was 87.50% in the observation group and 60.00% in the control group, with significant difference between the two groups (χ ~ 2 = 6.116, P <0.05). The observation group had significantly higher efficacy than the control group The incidence of adverse reactions in the observation group (10.96%) was significantly lower than that in the control group (25.68%) (χ ~ 2 = 5.308, P <0.05) . CONCLUSION: Caspofungin is effective in treating leukemia with pulmonary invasive fungal infection. It has strong antifungal effect and low incidence of adverse reactions.